IR情報

2018/09/07~2019/02/07

IR情報&株価推移

日付始値高値安値終値前日比出来高時価総額25日乖離
2019
02/148:30 2018年12月期決算短信〔米国基準〕(連結)
02/07938947917921-2.95%129,800387億5688万-7.34%
02/06952972940949+0.85%70,800399億3515万-4.33%
02/05970974936941-3.19%130,000395億9850万-4.66%
02/049799909689720%49,300409億302万-1.02%
02/01978999951972-0.51%57,400409億302万-0.61%
01/31955995950977+5.51%108,600411億1343万+0.31%
01/30955965912926-6.28%250,900389億6728万-5.03%
01/299831,010980988-1.1%81,000415億7633万+0.92%
01/281,0201,022993999-2.06%53,500420億3922万+1.94%
01/251,0021,0311,0021,020+2%68,900429億2293万+3.98%
01/249831,0159741,000+0.2%79,600420億8130万+1.73%
01/231,0001,015982998-2.92%127,800419億9714万+1.42%
01/238:00 定時株主総会にかかる基準日のお知らせ
01/221,0801,1091,0201,028+0.88%269,200432億5958万+4.47%
01/228:00 MN-166とリルゾール併用療法でのALS(筋萎縮性側索硬化症)およびその他の神経変性疾患を適応とする特許承認のお知らせ
01/211,0741,0881,0101,019-6.43%166,500428億8085万+3.77%
01/181,1011,1101,0811,089-1%141,600456億874万+10.9%
01/171,0881,1101,0731,100+3%281,700460億6943万+12.13%
01/1615:30 平成30年12月期決算説明会の開始時間変更に関するお知らせ
01/1615:30 ストックオプション(新株予約権)の発行に関するお知らせ
01/161,0501,0881,0421,068+2.3%171,000447億2923万+8.87%
01/151,0281,0531,0001,044+0.19%131,500437億2408万+6.31%
01/111,0021,0459921,042+4.72%181,000436億4032万+5.89%
01/101,0211,022989995-0.6%128,200416億7189万+0.81%
01/0915:30 平成30年12月期決算発表および決算説明会のお知らせ
01/091,0531,0539901,001-2.34%261,000419億2318万+0.81%
01/098:00 再発性グリオブラストーマ(神経膠芽腫(GBM))を適応とするMN-166(イブジラスト)とTMZ(テモゾロミド)の併用療法の患者登録開始のおしらせ
01/089871,0379611,025+8.35%281,200429億2833万+2.71%
01/088:00 MN-001及びMN-002の“線維症・線維化疾患”を適応とする日本における特許承認のお知らせ
01/07970980939946+0.85%127,200396億1971万-5.68%
01/04860969843938+4.57%164,000392億8466万-7.13%
2018
12/28865897850897+2.75%162,900375億6753万-11.63%
12/27863884841873+6.59%221,000365億6238万-14.58%
12/26840849795819+0.86%225,000343億78万-20.49%
12/25850858794812-7.52%576,600340億762万-22.07%
12/21839948791878+0.34%396,500367億7178万-16.7%
12/20975975849875-12.41%664,500366億4614万-17.84%
12/191,0191,019990999-1.28%90,200418億3942万-7.07%
12/181,0341,0419991,012-1.08%127,100423億8388万-6.3%
12/179991,0339971,023-0.2%73,700428億4457万-5.63%
12/141,0451,0551,0051,025-3.39%94,900429億2833万-6.05%
12/131,0601,0701,0281,061+2.22%170,400444億3606万-3.55%
12/1220:00 J.P.モルガン・ヘルスケア・カンファレンス2019への参加のお知らせ
12/121,0101,0441,0071,038+5.49%91,600434億7279万-6.57%
12/119881,007974984+0.41%147,700412億1120万-12.22%
12/101,0201,034963980-4.95%236,400410億4367万-13.27%
12/071,0781,0781,0241,031-2.27%104,400431億7962万-9.48%
12/061,0881,1001,0331,055-4%166,700441億8477万-7.86%
12/051,0921,1171,0801,099+0.73%120,200460億2755万-4.18%
12/041,1031,1241,0881,091-1.18%154,200456億9250万-4.63%
12/031,1201,1251,0911,104-1.43%150,600462億3696万-3.33%
11/301,1331,1501,1001,120-2.18%117,500469億706万-1.67%
11/291,1491,1561,1321,145+1.42%115,600479億5409万+0.88%
11/281,1401,1471,1231,129-1.74%92,300472億8399万-0.62%
11/271,1331,1571,1191,149+4.08%149,600481億2162万+1.14%
11/261,0981,1091,0771,104+2.32%83,200462億3696万-2.99%
11/221,0641,0951,0461,079+2.08%114,300451億8992万-5.52%
11/2115:30 TOKYO MX(東京メトロポリタンテレビジョン)「ザ・ビジョナリー~異才の花押~」当社社長兼CEO岩城裕一の出演のお知らせ
11/211,0551,0791,0461,057-3.12%162,100442億6854万-8.01%
11/201,1001,1101,0891,091-2.33%90,400456億9006万-5.79%
11/191,0751,1371,0721,117+0.27%167,000467億7892万-4.2%
11/161,1361,1491,1001,114-2.02%87,900466億5328万-4.95%
11/151,0851,1451,0821,1370%139,900476億1650万-3.48%
11/141,1581,1801,1311,137+0.71%156,400476億1650万-3.73%
11/131,0511,1751,0511,129+2.54%274,500472億8147万-4.97%
11/121,1531,1691,0971,101-8.02%344,100461億885万-8.1%
11/091,2101,2331,1801,197-4.01%359,500501億2925万-1.16%
11/081,3501,3551,2351,247-6.45%601,700522億2320万+2.3%
11/071,3151,3771,3091,333+2.62%371,500558億2480万+8.82%
11/061,2101,3001,2101,299+7.71%247,600544億91万+5.61%
11/051,1981,2351,1961,206+0.75%115,100505億616万-2.51%
11/021,2051,2211,1801,197+1.01%188,400501億2925万-3.86%
11/011,1001,2241,0731,185+7.73%167,500496億2670万-5.28%
10/311,0791,1151,0611,100+6.18%200,600460億6698万-12.7%
10/309901,0689831,036+1.07%230,400433億8671万-18.3%
10/291,0501,0701,0051,025-1.54%142,600429億2604万-19.92%
10/261,0501,0689911,041+2.26%249,500435億9611万-19.36%
10/268:30 2018年12月期第3四半期決算短信〔米国基準〕(連結)
10/251,0491,0851,0091,018-12.92%504,600426億3289万-21.63%
10/241,1451,1731,1021,169+2.54%225,900489億5663万-10.7%
10/231,1851,2051,1391,140-4.52%205,800477億4214万-13.18%
10/221,1811,2061,1551,194-1.49%238,500500億361万-9.48%
10/1915:30 四半期報告書の提出期限延長に関する書面の提出のお知らせ
10/191,2181,2231,1821,212-3.04%253,300507億5743万-8.25%
10/181,2841,2841,2481,250-2.19%106,300523億4884万-5.59%
10/171,3091,3091,2781,278-0.08%114,900535億2145万-3.62%
10/161,2901,2951,2651,279-0.23%78,200535億6333万-3.54%
10/151,2731,3001,2401,282+0.94%153,100536億8897万-3.32%
10/121,1841,2861,1831,270+4.79%192,900531億8642万-4.3%
10/111,1961,2451,1501,212-7.27%517,200507億5743万-9.01%
10/101,3551,3921,2961,307-5.08%338,100547億3594万-2.46%
10/091,3731,4041,3541,377-3.57%239,300576億6748万+2.76%
10/051,3821,4711,3681,428+2.44%400,400598億331万+6.73%
10/058:00 MN-166のグリオブラストーマ(神経膠芽腫)治療適応に対するFDAのオーファンドラッグ指定のお知らせ
10/041,4001,4181,3881,394-0.57%123,400583億7942万+4.58%
10/048:00 BioJapan 2018にて登壇のお知らせ
10/031,4101,4201,3681,402-2.77%240,900587億1446万+5.73%
10/021,4701,4781,4181,442-2.37%323,300603億8962万+9.33%
10/0119:00 従業員株式購入プランの実施(新株発行)に関するお知らせ
10/011,4371,4771,4261,477+5.35%562,100618億5539万+12.75%
09/281,3801,4201,3791,402+2.71%293,900587億1446万+8.26%
09/271,3881,3981,3621,365-2.08%240,500571億6493万+6.72%
09/261,3821,4501,3601,394+6.49%698,600583億7942万+10.2%
09/268:00 ALS(筋萎縮性側索硬化症)を適応とするMN-166のフェーズ3臨床試験に関するFDAからのポジティブなフィードバック受領のお知らせ
09/251,3001,3111,2871,309-1.06%151,800548億1970万+4.8%
09/211,3491,3581,3021,323+0.23%210,700554億601万+6.95%
09/201,2561,3881,2511,320+7.06%493,500552億8037万+7.84%
09/191,2481,2501,2241,233-2.14%116,900516億3689万+1.73%
09/198:00 Ladenburg Thalmannの2018年ヘルスケア・カンファレンスへの参加のお知らせ
09/181,2751,2791,2501,260-1.25%90,400527億6763万+4.48%
09/141,2801,3041,2681,276-0.93%86,000534億3769万+6.6%
09/131,2301,2911,2251,288+3.54%97,800539億4024万+8.33%
09/121,2661,2771,2131,244-2.81%177,900520億9756万+5.33%
09/111,3051,3101,2801,280-2.51%140,100536億521万+9.12%
09/101,3001,3281,2681,313+2.18%144,900549億8722万+12.9%
09/071,2301,2901,2161,285+2.23%181,200538億1460万+11.64%
09/058:00 モルガン・スタンレー・グローバル・ヘルスケア・カンファレンス2018への参加のお知らせ